Otsuka#39;s drug for Alzheimer#39;s disease agitation fails in late stage study
The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo.
The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo. The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo. Moneycontrol Latest News Read More
The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo.









